desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

Nigel Irwin; ZJ Franlin; Finbarr O'Harte

doi:10.1016/j.ejphar.2013.03.041

desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

Research output: Contribution to journal › Article › peer-review

Abstract

Glucagon is hormone secreted from the pancreatic alpha-cells that is involved in blood glucose regulation. As such, antagonism of glucagon receptor signalling represents an exciting approach for treating diabetes. To harness these beneficial metabolic effects, two novel glucagon analogues, desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon, has been evaluated for potential glucagon receptor antagonistic properties. Both novel peptides were completely resistant to enzymatic breakdown and significantly (P

Original language	English
Pages (from-to)	43-51
Journal	European Journal of Pharmacology
Volume	709
Issue number	1-3
DOIs	https://doi.org/10.1016/j.ejphar.2013.03.041
Publication status	Published (in print/issue) - 2 Apr 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejphar.2013.03.041

Cite this

@article{53fc91aa161943139a1c824d9d5bb9f5,

title = "desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.",

abstract = "Glucagon is hormone secreted from the pancreatic alpha-cells that is involved in blood glucose regulation. As such, antagonism of glucagon receptor signalling represents an exciting approach for treating diabetes. To harness these beneficial metabolic effects, two novel glucagon analogues, desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon, has been evaluated for potential glucagon receptor antagonistic properties. Both novel peptides were completely resistant to enzymatic breakdown and significantly (P",

author = "Nigel Irwin and ZJ Franlin and Finbarr O'Harte",

year = "2013",

month = apr,

day = "2",

doi = "10.1016/j.ejphar.2013.03.041",

language = "English",

volume = "709",

pages = "43--51",

journal = "European Journal of Pharmacology",

issn = "1879-0712",

publisher = "Elsevier BV",

number = "1-3",

}

desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity. / Irwin, Nigel; Franlin, ZJ; O'Harte, Finbarr.
In: European Journal of Pharmacology, Vol. 709, No. 1-3, 02.04.2013, p. 43-51.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

AU - Irwin, Nigel

AU - Franlin, ZJ

AU - O'Harte, Finbarr

PY - 2013/4/2

Y1 - 2013/4/2

N2 - Glucagon is hormone secreted from the pancreatic alpha-cells that is involved in blood glucose regulation. As such, antagonism of glucagon receptor signalling represents an exciting approach for treating diabetes. To harness these beneficial metabolic effects, two novel glucagon analogues, desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon, has been evaluated for potential glucagon receptor antagonistic properties. Both novel peptides were completely resistant to enzymatic breakdown and significantly (P

AB - Glucagon is hormone secreted from the pancreatic alpha-cells that is involved in blood glucose regulation. As such, antagonism of glucagon receptor signalling represents an exciting approach for treating diabetes. To harness these beneficial metabolic effects, two novel glucagon analogues, desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon, has been evaluated for potential glucagon receptor antagonistic properties. Both novel peptides were completely resistant to enzymatic breakdown and significantly (P

U2 - 10.1016/j.ejphar.2013.03.041

DO - 10.1016/j.ejphar.2013.03.041

M3 - Article

SN - 1879-0712

VL - 709

SP - 43

EP - 51

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 1-3

ER -

desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this